NCT06418529

A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis

Comparative Effectiveness of New Initiators of Tofacitinib and Other Biologic/Targeted Synthetic DMARDs in Patients With Rheumatoid Arthritis

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 21,340 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to learn how different types of medicines may improve disease activity in people with rheumatoid arthritis (RA). RA is a kind of joint disease that causes pain and swelling. The study will look at data from a large, US-based group of RA patients who have taken the below medicines: * Tofacitinib * Abatacept * Tocilizumab or sarilumab The study will compare clinical disease activity scores of patients on the different medicines taken. The study will also decide whether some patient traits or disease factors play a role in how medicines may improve disease activity.

Conditions

• Rheumatoid Arthritis

Interventions

Type	Name	Description
DRUG	tofacitinib	New index treatment of tofacitinib
DRUG	tumor necrosis factor inhibitors (TNFi)	New index treatment of TNFi
DRUG	abatacept	New index treatment of abatacept
DRUG	tocilizumab or sarilumab	New index treatment of tocilizumab or sarilumab

Timeline

• Start date: 2024-05-15
• Primary completion: 2024-07-19
• Completion: 2024-07-19
• First posted: 2024-05-17
• Last updated: 2025-07-31
• Results posted: 2025-07-31

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study